According to MedPage Today (9/12, DePeau-Wilson), psychiatric care professionals “most often ranked the side effect profile of long-acting injectables (LAIs) for schizophrenia as the top consideration when prescribing the antipsychotics to patients,” researchers concluded in the findings of a 380-respondent, “survey-based study” presented in a poster at Psych Congress 2023. Among those respondents, “33% cited the safety/tolerability profile as key when selecting an LAI, with 16% to 21% of the respondents citing patient preference, the particular molecule in the LAI, access, or product attributes like dosing intervals or injection site as most important.”

Related Links:

— MedPage Today (requires login and subscription)

MedPage Today (9/11, DePeau-Wilson) reports, “Every-six-month dosing of the long-acting injectable paliperidone palmitate (Invega Hafyera) for schizophrenia was effective and safe up to three years, researchers reported” in “an intention-to-treat analysis that included 121 patients.” The study revealed that “95.9% on the twice-a-year dose of the atypical antipsychotic remained relapse-free.” The findings were presented in a poster at Psych Congress 2023.

Related Links:

— MedPage Today (requires login and subscription)

MedPage Today (9/11, DePeau-Wilson) reports, “People with narcolepsy frequently had mood and pain comorbidities that complicated diagnosis and treatment plans,” investigators concluded. In “a propensity-matched cohort analysis of more than 4,000 individuals,” researchers found that “people with narcolepsy were more than twice as likely to be diagnosed with depression” or “chronic pain syndrome.” The findings were presented at Psych Congress 2023.

Related Links:

— MedPage Today (requires login and subscription)

Healio (9/11, Weldon) reports, “Both victims and perpetrators of cyberbullying are more likely than other youths to experience eating disorder symptoms,” researchers concluded after studying “responses from 10,258 adolescents in the U.S. aged 10 to 14 years who answered questions about whether they had experienced cyberbullying – as a victim or perpetrator – and whether they had experienced eating disorder symptoms.” The findings were published online Sept. 6 in the International Journal of Eating Disorders.

Related Links:

— “Eating disorders affect victims and perpetrators of cyberbullying,”Rose Weldon, Healio, September 11, 2023

MedPage Today (9/9, Monaco) reported, “Youth with attention-deficit/hyperactivity disorder” (AD/HD) “saw mildly different growth trajectories with certain popular medications, researchers reported” in findings presented in a poster at Psych Congress 2023. The study revealed that when “compared with youth prescribed lisdexamfetamine dimesylate (LDX; Vyvanse), those who took delayed release/extended-release methylphenidate (DR/ER-MPH; Jornay PM) saw a greater weight trajectory in the first year after starting treatment.” Included in the final study sample were “83 patients on DR/ER-MPH, 240 on OROS MPH, and 403 on LDX.”

Related Links:

— MedPage Today (requires login and subscription)